Etravirine plus Darunavir/r as Dual Therapy

INROADS Trial
Etravirine + Darunavir/r as Dual Therapy
INROADS: Design

**Study Design: INROADS**

- **Background**: Phase 2b, single-arm trial evaluating etravirine with darunavir plus ritonavir in treatment-experienced subjects or treatment-naïve subjects with transmitted resistance

- **Inclusion Criteria (n = 54)**
  - Age ≥18
  - Treatment-naïve: resistance to either efavirenz or nevirapine, but no resistance to etravirine darunavir
  - Treatment-experienced subjects
  - HIV RNA >500 copies/mL
  - CD4 count ≥50 cells/mm³

- **Treatment Arms (all taken once daily)**
  - Etravirine 400 mg + Darunavir 800 mg + RTV 100 mg

* INROADS = Intelencef aNd pRezista Oncnce A Day Study

Etravirine + Darunavir/r as Dual Therapy
INROADS: Result

Week 48: Virologic Response

CVR = confirmed virologic response; TLOVR = Time to loss of virologic; ITT: Intent-to-Treat.
CVR allows patients who are resuppressed after failure to be counted as virologic responders.

**Conclusions:** “Etravirine 400 mg and darunavir/ritonavir 800/100 mg as a two-drug once-daily regimen in treatment-experienced subjects or treatment-naïve subjects with transmitted resistance was virologically efficacious and well tolerated.”
Acknowledgment

The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.